Post-hoc pairwise comparisons indicated that hit rates in the galantamine group were significantly higher than in the levodopa group (p = 0.019; the difference to the placebo group failed to reach significance: p = 0.06).
Further to what is listed as major concerns by both reviewers below, (2a) A major concern that arose in the editorial-reviewer discussions is the following: The biperiden effects are either non-significant vs placebo or just at the threshold of significance (SVC) in samples of ~25 per group, so we deem it unlikely that these effects could be very informative at the individual level.